在巨细胞中识别VISTA调节器,调解癌细胞存活率
Abdalla M Abdrabou1,2,3, Sharif U Ahmed4, Mengqi Jonathan Fan2
1Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Science advances
|November 27, 2024
概括
研究人员确定了AhR和IRAK1的关键调节剂,这些调节剂可以控制巨细胞上V域免疫球蛋白抑制T细胞激活 (VISTA) 的作用. 抑制这些可以促进抗瘤免疫反应,克服对免疫检查点阻塞 (ICB) 癌症疗法的抵抗力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫检查点阻塞 (ICB) 疗法是一种有前途的癌症治疗方法,但耐药性很常见.
- 瘤微环境 (TME) 中的免疫抑制巨细胞对ICB抵抗有显著的贡献.
- 维域免疫球蛋白抑制T细胞激活剂 (VISTA) 是巨体表达的关键免疫抑制分子.
研究的目的:
- 为了确定V域免疫球蛋白抑制T细胞激活 (VISTA) 在巨细胞表达的新型调节剂.
- 开发一种策略,通过调节巨细胞表型来克服对免疫检查点阻塞 (ICB) 疗法的耐药性.
主要方法:
- 利用高通量微流体平台进行全基因组的CRISPR淘汰查,以识别VISTA调节器.
- 在巨细胞中对已识别的命中物进行了功能性表征.
- 在癌症的临床前小鼠模型中,针对性确定调节剂 (AhR和IRAK1).
主要成果:
- 确定了阿里碳化合物受体 (AhR) 和介素-1受体相关激酶1 (IRAK1) 作为VISTA的关键调节剂.
- 击败AhR和IRAK1降低了巨细胞上的VISTA表面水平,促进了抗瘤表型.
- 向AhR和IRAK1在体内使瘤对ICB治疗敏感,增加细胞毒性CD8+T细胞,NK细胞和抗瘤巨细胞的透.
结论:
- 艾哈和IRAK1是VISTA的关键调节者,协调抗瘤免疫的障碍.
- 抑制AhR和IRAK1是一种可行的策略,通过重编程巨细胞来提高ICB疗法的疗效.
- 这种方法有可能克服各种人类癌症的耐药性.
相关概念视频
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K


